Herman Groen

IQ Therapeutics' mission to become a leading biopharmaceutical company developing antibody based products for the prevention and treatment of infectious diseases and for biodefense. IQ Therapeutics has developed a proprietary technology for the generation of fully human antibodies from the blood of vaccinated or immunized donors. It is its philosophy that the most physiological origin for antibodies to be applied as therapeutic agent inside a human body is the human body itself. The human immune response is the basis for its technology and therefore they have termed it 'Cloning the Human Response TM'. Its aim is to apply this technology for the generation of protective antibodies which can serve as passive immunization to protect humans against infectious diseases and biodefense, thus providing 'instant immunity'. For Anthrax infections they have developed human monoclonal antibodies directed against two components of the lethal toxin, PA and LF. Both antibodies fully protect animals when given before or after exposure. IQ has taken its unique anti-LF antibody as its lead product for drug development towards registration. 'Cloning the Human ResponseTM' is also applied for various in-house developments to build a pipeline of potential novel antibody based drugs. Moreover, they offer the technology as service for third parties.

IQ Corporation is a life sciences company based in The Netherlands. Its mission is to contribute to human healthcare through the development and worldwide commercialization of products for diagnostic and therapeutic applications. The company's therapeutics division (IQ Therapeutics) is applying its Cloning the Human Response(TM) technology for its own pipeline and third parties' to generate and develop fully human antibodies from immunized or vaccinated donors for the prevention and treatment of infectious diseases. The company's diagnostic products division (IQ Products www.iqproducts.nl) has developed a range of products for flow-cytometry and for perinatal, transplantation and sepsis related diagnosis, which are sold in more than 50 countries. NOM NV and Zernike Seed Fund BV are the major shareholders in IQ Corporation.